Application of methylophiopogon japonicus flavone A derivatives in preparation of medicines for preventing and treating liver diseases
By using methyloporubic flavonoids Class A derivatives and their pharmaceutical compositions, the problem of insufficient treatment in the field of liver inflammation prevention and treatment is solved, and a significant inhibitory effect on liver cell damage and apoptosis is provided, which significantly improves the treatment plan for liver disease. .
Patent Information
- Application Number
- CN202310635871.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-31
- Publication Date
- 2024-12-03
AI Technical Summary
The prior art has made unsatisfactory progress in the prevention and treatment of liver inflammation, and there are limited clinically available treatment drugs and means for liver disease, especially in the lack of effective drugs for anti-inflammatory and liver protection.
Use methyl Ophiopogonis flavonoids Class A derivatives and pharmaceutical compositions and are used to prevent and treat hepatitis A, hepatitis B, hepatitis C, drug-related fatty liver disease, alcoholic liver disease, Liver diseases such as autoimmune liver disease significantly protect hepatocytes and inhibit hepatocyte damage and apoptosis.
Methyl Ophiopogonis flavonoids Class A derivative significantly inhibits human hepatocyte damage induced by hydrogen peroxide, improves cell survival, reduces the level of cell damage biomarkers, and significantly inhibits apoptosis, providing a new treatment plan for liver disease.
Smart Images

Figure CN119055633A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology. The present invention relates to new medical uses of methyl ophiopogon flavonoids class A derivatives represented by formula I and formula II, specifically new uses of methyl ophiopogon flavonoids class A derivatives in drugs for preventing and / or treating liver diseases.
[0002] Background Art
[0003] In recent years, the incidence of drug-induced liver disease, alcoholic liver disease, metabolic-related fatty liver disease, and autoimmune liver disease has also been increasing annually. As is well known, liver disease is a progressive condition. Numerous lines of evidence suggest that liver damage and inflammation occur in virtually all causes of liver disease and often persist throughout the course of the disease. Oxidative stress is a key mechanism, and anti-inflammatory and hepatoprotective drugs with hepatocellular protective activity play a crucial role in the comprehensive treatment of liver disease. In 2014, the Expert Committee on Liver Inflammation and Its Prevention and Treatment of the Chinese Society of Infectious Diseases published the "Expert Consensus on Liver Inflammation and Its Prevention and Treatment." This consensus states: "Liver inflammation and the resulting liver fibrosis, cirrhosis, and liver failure are the primary pathophysiological and histopathological basis for the progression of liver disease. Anti-inflammatory and hepatoprotective therapy is an essential component of the comprehensive treatment of liver inflammation. For patients with liver inflammation, regardless of the availability of effective causal therapy, anti-inflammatory and hepatoprotective therapy should be considered, especially for patients who lack effective causal therapy or for whom causal therapy is temporarily unavailable." However, for a long time, research on the prevention and treatment of liver inflammation, especially anti-inflammatory and liver protection, has not made ideal progress, and the clinical options for liver disease treatment are limited.
[0004] Independent intellectual property rights have been applied for in my country for methyl ophiopogon japonicus flavonoids A derivatives (Formula I, Formula II) with therapeutic effects on cardiovascular diseases. Recent research has found that methyl ophiopogon japonicus flavonoids A derivatives (Formula I, Formula II) have significant protective activity against hepatocellular damage. This patent application has been filed. Summary of the Invention
[0005] The present invention provides a class of methyl ophiopogon flavonoids Class A derivatives and pharmaceutical compositions containing the same for use in preparing drugs for preventing and / or treating liver diseases. The pharmaceutical composition comprises a class of methyl ophiopogon flavonoids Class A derivatives or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier or excipient; the pharmaceutical composition comprises tablets, capsules, granules, pills, drop pills, pre-emulsions, microemulsions, suspensions, syrups, enteric-coated preparations, or injections; and the liver disease is selected from hepatitis A, hepatitis B, hepatitis C, drug-induced liver disease, metabolic-related fatty liver disease, alcoholic liver disease, autoimmune liver disease, progressive liver fibrosis, cirrhosis, and liver failure.
[0006] In order to solve the technical problem of the present invention, the present invention adopts the following technical solution:
[0007] The first aspect of the technical solution of the present invention provides the use of a methyl ophiopogon japonicus flavonoids Class A derivative as described in Formula I or Formula II or a pharmaceutically acceptable salt thereof in the preparation of a drug for preventing and / or treating liver diseases. The compound structure is as follows:
[0008]
[0009] A second aspect of the technical solution of the present invention provides the use of a pharmaceutical composition containing the methyl ophiopogon japonicus flavonoids Class A compound described in the first aspect in the preparation of a medicament for preventing and / or treating liver disease. The pharmaceutical composition can be prepared according to methods well known in the art. The compound of the present invention can be combined with one or more pharmaceutically acceptable solid or liquid excipients and / or adjuvants to form any dosage form suitable for human or animal use. The content of the compound of the present invention in the pharmaceutical composition is generally 0.1-95% by weight.
[0010] The compound of the present invention or the pharmaceutical composition containing the same can be administered in unit dosage form, and the administration route can be enteral or parenteral, such as oral, intravenous, intramuscular, subcutaneous, nasal, oral mucosa, eyes, lungs and respiratory tract, skin, vagina, rectum, etc.
[0011] The dosage form can be a liquid dosage form, a solid dosage form, or a semisolid dosage form. Liquid dosage forms can be solutions (including true solutions and colloidal solutions), emulsions (including o / w, w / o, and multiple emulsions), suspensions, injections (including aqueous injections, powder injections, and infusions), eye drops, nasal drops, lotions, and liniments; solid dosage forms can be tablets (including ordinary tablets, enteric-coated tablets, lozenges, dispersible tablets, chewable tablets, effervescent tablets, and orally disintegrating tablets), capsules (including hard capsules, soft capsules, and enteric-coated capsules), granules, powders, micropills, dropping pills, suppositories, films, patches, aerosols (powders), and sprays; semisolid dosage forms can be ointments, gels, pastes, and the like.
[0012] The compound of the present invention can be prepared into common preparations, sustained-release preparations, controlled-release preparations, targeted preparations and various microparticle drug delivery systems.
[0013] In order to prepare the compound of the present invention into tablets, various excipients well known in the art can be widely used, including diluents, binders, wetting agents, disintegrants, lubricants, and glidants. Diluents can be starch, dextrin, sucrose, glucose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, calcium sulfate, calcium hydrogen phosphate, calcium carbonate, etc.; wetting agents can be water, ethanol, isopropyl alcohol, etc.; binders can be starch slurry, dextrin, syrup, honey, glucose solution, microcrystalline cellulose, acacia slurry, gelatin slurry, sodium carboxymethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, ethyl cellulose, acrylic resin, carbomer, polyvinyl pyrrolidone, polyethylene glycol, etc.; disintegrants can be dry starch, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, cross-linked polyvinyl pyrrolidone, cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch, sodium bicarbonate and citric acid, polyoxyethylene sorbitan fatty acid ester, sodium lauryl sulfate, etc.; lubricants and glidants can be talc, silicon dioxide, stearate, tartaric acid, liquid paraffin, polyethylene glycol, etc.
[0014] The tablets can be further made into coated tablets, such as sugar-coated tablets, film-coated tablets, enteric-coated tablets, or double-layer tablets and multi-layer tablets.
[0015] To prepare the dosing unit as a capsule, the active ingredient compound of the present invention can be mixed with a diluent and a glidant, and the mixture can be directly placed in a hard or soft capsule. Alternatively, the active ingredient compound of the present invention can be first mixed with a diluent, a binder, and a disintegrant to form granules or pellets, which are then placed in a hard or soft capsule. The diluents, binders, wetting agents, disintegrants, and glidants used to prepare tablets of the compound of the present invention can also be used to prepare capsules of the compound of the present invention.
[0016] To prepare the compounds of the present invention as injections, water, ethanol, isopropanol, propylene glycol, or mixtures thereof can be used as solvents, and appropriate amounts of solubilizers, cosolvents, pH adjusters, and osmotic pressure regulators commonly used in the art can be added. Examples of solubilizers or cosolvents include poloxamer, lecithin, and hydroxypropyl-β-cyclodextrin; pH adjusters include phosphates, acetates, hydrochloric acid, and sodium hydroxide; and osmotic pressure regulators include sodium chloride, mannitol, glucose, phosphates, and acetates. For lyophilized powder injections, mannitol, glucose, and the like can also be added as support agents.
[0017] Furthermore, if necessary, colorants, preservatives, perfumes, flavorings or other additives may be added to the pharmaceutical preparations.
[0018] To achieve the purpose of medication and enhance the therapeutic effect, the drug or pharmaceutical composition of the present invention can be administered by any known method of administration.
[0019] The dosage of the pharmaceutical composition of the compound of the present invention may vary widely depending on the nature and severity of the disease to be prevented or treated, the individual condition of the patient or animal, the route of administration, and the dosage form. Generally speaking, a suitable daily dosage range of the compound of the present invention is 0.001-150 mg / kg body weight, preferably 0.1-100 mg / kg body weight, more preferably 1-60 mg / kg body weight, and most preferably 2-30 mg / kg body weight. The above dosage may be administered in one dosage unit or divided into several dosage units, depending on the physician's clinical experience and the dosage regimen including the use of other therapeutic means.
[0020] The compound or composition of the present invention can be taken alone or in combination with other therapeutic drugs or symptomatic drugs. When the compound of the present invention has a synergistic effect with other therapeutic drugs, its dosage should be adjusted according to the actual situation.
[0021] Beneficial technical effects:
[0022] 1. The present invention provides a new use of a class of methyl ophiopogon flavonoids A derivatives in the preparation of drugs for preventing and / or treating liver diseases.
[0023] 2. Experiments have shown that the compounds described in the present invention have the following significant pharmacological activities: they have significant inhibitory activity on hydrogen peroxide (H2O2)-induced human hepatocyte damage, can significantly increase cell survival rate, and significantly reduce the levels of liver injury biomarkers in cell culture supernatant; they have significant inhibitory activity on hydrogen peroxide (H2O2)-induced human hepatocyte apoptosis. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 Flow cytometric images of the inhibitory activity of methyl ophiopogon flavonoids A derivatives on hydrogen peroxide (H2O2)-induced apoptosis in human hepatocytes. DETAILED DESCRIPTION
[0025] The following examples and pharmacological activity experiments are only used to further illustrate the present invention, but do not mean any limitation of the present invention. Experimental methods without specific conditions in the following examples were performed according to conventional methods and conditions, or selected according to the product specifications.
[0026] In the following examples, the corresponding Chinese names of some substances are as follows:
[0027] Control: blank control
[0028] Model: Model comparison
[0029] H2O2: Hydrogen peroxide
[0030] GSH: Glutathione
[0031] AST: aspartate aminotransferase
[0032] ALP: alkaline phosphatase
[0033] The room temperature described in the following examples is generally 15-25°C as commonly used in the art.
[0034] Experimental Example 1 Activity test of methyl ophiopogon flavonoids A derivatives in hydrogen peroxide (H2O2)-induced hepatocyte injury model
[0035] Experimental methods:
[0036] Human hepatocytes HepG2 cells in logarithmic growth phase were collected, 7×10 4 Cells were inoculated with 100 μL of each well in a 96-well plate. The cells were divided into four parallel wells: a blank control group, a hydrogen peroxide (H2O2) group, a H2O2 + glutathione (GSH) 40 μM group, a H2O2 + Formula I 0.5 μM group, a H2O2 + Formula I 1 μM group, a H2O2 + Formula I 5 μM group, a H2O2 + Formula II 0.5 μM group, a H2O2 + Formula II 1 μM group, and a H2O2 + Formula II 5 μM group. After 24 hours of incubation, the corresponding dose of drug was added to each treatment group. After incubation for 12 hours, hydrogen peroxide (H2O2, final concentration 400 μM) was added to all groups except the blank control group and allowed to act for another 12 hours. Remove the supernatant and add 100 μL of CCK solution to each well (CCK volume accounts for 10% of the DMEM volume). Incubate in a cell incubator for 1 hour. Measure absorbance at 450 nm on a microplate reader to calculate cell viability. Cell viability = (experimental well - no-cell blank well) / (control well - no-cell blank well) × 100%.
[0037] Experimental results:
[0038] The results are shown in Table 1. Compared with the blank control group, H2O2 at 400μM caused significant damage to human hepatocytes, with a cell survival rate of only 37.09%. Formula I at 0.5μM, 1μM, and 5μM, and Formula II at 0.5μM, 1μM, and 5μM, all showed significant protective activity against H2O2-induced damage in human hepatocytes, significantly increasing cell survival rates. These activities were statistically significant compared to the model group, and were superior to the positive control drug GSH at 40μM.
[0039] Table 1 Protective effect of flavonoids A derivatives of methyl ophiopogon on liver injury caused by hydrogen peroxide (n=4)
[0040]
[0041] *** P < 0.001, compared with the blank control group; # P<0.05, ###P<0.001, compared with the model group.
[0042] Experimental Example 2 Activity Test of Damage-Related Biomarkers in the Culture Supernatant of Human Hepatocyte Model Injured by Hydrogen Peroxide (H2O2)
[0043] Experimental methods:
[0044] HepG2 cells in the logarithmic growth phase, 1.4×10 5 Cells were inoculated with 2 mL of DMSO per well in a 6-well plate. The cells were divided into three groups: a blank control group, a hydrogen peroxide (H2O2) group, a H2O2 + glutathione (GSH) 40 μM group, a H2O2 + Formula I 0.5 μM group, a H2O2 + Formula I 1 μM group, a H2O2 + Formula II 0.5 μM group, and a H2O2 + Formula II 1 μM group, with three replicate wells per group. After 24 hours of incubation, the drug-treated groups were treated with the corresponding doses of Formula I, Formula II, and GSH, while the blank control and model groups were treated with an equal volume of DMSO. After 12 hours of drug incubation, hydrogen peroxide (H2O2, final concentration 400 μM) was added to all other groups except the blank control group, and the cells were exposed for another 12 hours.
[0045] The supernatant was collected in a 1.5 mL centrifuge tube, and the AST and ALP levels in the cell culture supernatant were detected using a Japanese TOSHIBA automatic biochemical analyzer (model: TBA-40FR) according to the kit instructions.
[0046] Experimental results:
[0047] The results are shown in Table 2. Compared with the blank control group, the levels of injury-related biomarkers in the supernatant of H2O2-damaged human hepatocytes were significantly elevated. Formula I at 0.5μM and 1μM, and Formula II at 0.5μM and 1μM, significantly reduced AST and ALP levels in the cell supernatant, demonstrating statistically significant differences compared to the model group, demonstrating significant protective activity against hepatocellular injury. Formula II was more active than the positive control drug GSH at 40μM.
[0048] Table 2 Protective effect of methyl ophiopogon flavonoids A derivatives on HepG2 hepatocytes damaged by hydrogen peroxide (n=3)
[0049]
[0050] *** P<0.001 compared with the blank control group; # P<0.05, ## P<0.01, ### P<0.001 compared with the model group. Experimental Example 3 Activity test of methyl ophiopogon flavonoids A derivatives in hydrogen peroxide (H2O2)-induced human hepatocyte apoptosis model
[0051] Experimental methods:
[0052] HepG2 cells in the logarithmic growth phase were cultured at a rate of 1.4×10 5 Cells were inoculated with 2 mL of glutathione (GSH) per well in a 6-well plate, divided into three groups: a blank control group, a hydrogen peroxide (H2O2) group, a H2O2 + glutathione (GSH) 40 μM group, a H2O2 + Formula I 0.5 μM group, a H2O2 + Formula I 1 μM group, a H2O2 + Formula II 0.5 μM group, and a H2O2 + Formula II 1 μM group, with three parallel wells per group. After 24 hours of incubation, Formula I, Formula II, and GSH were added to the drug-treated groups, respectively. An equal volume of DMSO was added to the blank control and H2O2 model groups. After 12 hours of drug incubation, hydrogen peroxide (H2O2, final concentration 400 μM) was added to all groups except the blank control group, and the cells were exposed to the drug for another 12 hours.
[0053] Collect cells in 1.5 mL centrifuge tubes and centrifuge at 2000 rpm at 4°C for 3 minutes. Remove the supernatant and wash with 1 mL of pre-chilled PBS per tube. Vortex to mix thoroughly and centrifuge three times. Add 500 μL of 1× Binding Buffer to the pellet, resuspend and mix thoroughly, and incubate on ice for 30 minutes. Stain with 10 μL of Annexin V-FITC and 5 μL of FITC dye per tube. Apoptosis analysis was performed using a BD flow cytometer (FASCVERSE).
[0054] Experimental results:
[0055] The results are shown in Table 3 and Appendix Figure 1 Compared with the blank control group, H2O2 at 400μM induced significant apoptosis in human hepatocytes, with a significantly increased percentage of apoptotic cells (18.40%). Formula I at 0.5μM and 1μM, and Formula II at 0.5μM and 1μM, exhibited significant inhibitory activity against H2O2-induced apoptosis in human hepatocytes, with a significantly decreased percentage of apoptotic cells, showing statistically significant differences compared with the model group.
[0056] Table 3 Effects of methyl ophiopogon flavonoids A derivatives on hydrogen peroxide-induced apoptosis in human hepatocytes (n=3)
[0057]
[0058] *** P < 0.001, compared with the blank control group; # P<0.05, ## P<0.01, compared with the model group.
Claims
1. Use of a class of methyl ophiopogon japonicus flavonoids A derivatives or pharmaceutically acceptable salts thereof as shown in formula I or formula II in the preparation of drugs for preventing and / or treating liver diseases; 2. Use of a pharmaceutical composition in the preparation of a drug for preventing and / or treating liver diseases, characterized in that: The pharmaceutical composition comprises a preventive and / or therapeutically effective amount of a class of methyl ophiopogon japonicus flavonoids class A derivatives or pharmaceutically acceptable salts thereof as claimed in claim 1, and optionally one or more pharmaceutically acceptable carriers or excipients.
3. The use according to claim 2, characterized in that The pharmaceutical composition includes tablets, capsules, granules, pills, dripping pills, pre-emulsions, microemulsions, suspensions, syrups, enteric-coated preparations, and injections.
4. The use according to any one of claims 1 to 3, characterized in that The liver disease is selected from hepatitis A, hepatitis B, hepatitis C, drug-induced liver disease, metabolism-related fatty liver disease, alcoholic liver disease, autoimmune liver disease, liver fibrosis, cirrhosis, and liver failure caused by progressive liver disease.
Citation Information
Patent Citations
Application of methylophiopogonone A to preparation of medicine for preventing and / or treating nonalcoholic fatty liver disease and liver injury
CN112294794A
Application of flavone derivative
CN112933076A
